N‑[3‑(2‑furyl)acryloyl]-L-phenylalanylglycylglycine | 64967-39-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N‑[3‑(2‑furyl)acryloyl]-L-phenylalanylglycylglycine
• 英文别名: N^α-3-(2-furyl)acryloyl-L-phenylalanyl-glycyl-glycine；N^α-furylacryloylphenylalanylglycylglycine；(N-(3-[2-furylacryloyl-Phe-Gly-Gly]))；(N-3-[2-furyl]acryloyl)-Phe-Gly-Gly；FAPGG；N-(3-[2-furyl]acryloyl)-l-phenylalanylglycylglycine；2-[[2-[[(2S)-2-[3-(furan-2-yl)prop-2-enoylamino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid
• CAS: 64967-39-1
• 化学式: C₂₀H₂₁N₃O₆
• 分子量: 399.403
• InChiKey: ZDLZKMDMBBMJLI-INIZCTEOSA-N

物化性质

• 熔点：
  245 °C (dec.)(lit.)
• 沸点：
  842.3±65.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)
• 溶解度：
  NH4OH1M：50 mg/mL，澄清至微浑浊，黄色

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29321900

反应信息

• 作为产物：
  描述：

  呋喃丙烯酸酐 在 氢氧化钾 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 N‑[3‑(2‑furyl)acryloyl]-L-phenylalanylglycylglycine
  参考文献：
  名称：

  Pozdnev, V. F., Journal of general chemistry of the USSR, 1986, vol. 56, p. 613 - 617

  摘要：

  DOI：

文献信息

• Porcane liver polypeptides for treating viral infections
  申请人：KREMERS- URBAN CO.

  公开号：EP0537722A2

  公开（公告）日：1993-04-21

  The present invention is directed to substantially pure peptide composition having antiviral activity. These peptides are characterized by having a molecular weight of from between 5,000 to 40,000 Daltons. These peptides are further characterized by having at its 5' end the amino acids shown in Sequence Id. No. 1 and its 3' end either Sequence Id. Nos. 4 or 6. Additionally, this peptide is further characterized at its 5' end by being coded for DNA sequence shown in Sequence Id. No. 3. This composition can be used to treat viral infections, in particular HIV and HHV-6.

  本发明涉及具有抗病毒活性的基本纯肽组合物。这些肽的特点是分子量在 5,000 到 40,000 道尔顿之间。这些多肽的进一步特征是其 5'端具有序列 Id.1 所示的氨基酸，其 3'端为序列 Id.4或6。此外，这种多肽 5'端的进一步特征是其 DNA 序列编码如序列同上第 3 号所示。3 所示的 DNA 序列编码。这种组合物可用于治疗病毒感染，特别是 HIV 和 HHV-6。
• The use of mammalian liver extract for the manufacture of a medicament to treat presenile or senile dementia
  申请人：KREMERS- URBAN CO.

  公开号：EP0554887A1

  公开（公告）日：1993-08-11

  A therapeutic method for treating Alzheimer's or related disease. The method comprises administering a therapeutically-effective amount of a mammalian liver extract, the extract being characterized by being heat stable, insoluble in acetone and soluble in water, peptide or peptide fragment selected from the groups consisting of Sequence Identification Numbers 1-9.

  一种治疗阿尔茨海默氏症或相关疾病的方法。该方法包括给药治疗有效量的哺乳动物肝脏提取物，该提取物的特点是热稳定、不溶于丙酮、可溶于水、多肽或多肽片段选自序列识别码 1-9 所组成的组。
• Metallo-proteinase inhibitory agent
  申请人：Société des Produits Nestlé S.A.

  公开号：EP1359157A1

  公开（公告）日：2003-11-05

  The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent comprising casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The invention also relates to the manufacture of a agent, in which a food grade bacteria of the genus Lactobacillus helveticus is contacted with casein in order to perform an hydrolysis and obtain casein-derivated peptides exhibiting metalloproteinases inhibitory property. The present invention also concern the isolated and purified inhibitory peptides obtained by hydrolysis of casein by the said bacteria.

  本发明涉及一种活性剂，特别是一种金属蛋白酶抑制剂，该活性剂包含通过食品级细菌水解酪蛋白而获得的酪蛋白衍生肽。本发明还涉及一种制剂的制造，在这种制剂中， helveticus 乳酸杆菌属的食品级细菌与酪蛋白接触，以进行水解并获得具有金属蛋白酶抑制特性的酪蛋白衍生肽。本发明还涉及通过上述细菌水解酪蛋白获得的分离和纯化的抑制肽。
• Diagnostics and therapeutics for macular degeneration
  申请人：UNIVERSITY OF IOWA RESEARCH FOUNDATION

  公开号：EP1804064A1

  公开（公告）日：2007-07-04

  The invention relates to diagnostics and therapeutics and animal models for macular degeneration, specifically as they relate to the association described herein between macular degeneration and arterial wall disruptive disorders. In one embodiment, the invention provides kits and methods for diagnosing macular degeneration comprising identifying a marker for an arterial wall disruptive disorder, including an aneurysm. In one embodiment, the invention provides therapeutics for treating macular degeneration comprising delivering to a subject an agent useful for treating an arterial wall disruptive disorder, including an aneurysm.

  本发明涉及黄斑变性的诊断和治疗方法及动物模型，特别是涉及本文所述的黄斑变性与动脉壁破坏性疾病之间的关联。在一个实施方案中，本发明提供了诊断黄斑变性的试剂盒和方法，包括鉴定动脉壁破坏性疾病（包括动脉瘤）的标记物。在一个实施方案中，本发明提供了用于治疗黄斑变性的疗法，包括向受试者提供用于治疗动脉壁破坏性疾病（包括动脉瘤）的药剂。
• Dilution based inhibition assay
  申请人：Debreceni Egyetem

  公开号：EP2664920A1

  公开（公告）日：2013-11-20

  The present invention provides for a process to assess the level of reversible inhibition of an enzyme by an inhibitor, in particular in the field of assessment the effectiveness of a medical treatment. In a particularly preferred embodiment the effectiveness of angiotensin converting enzyme (ACE) inhibitor (ACEi) therapy is disclosed. The invention also relates to uses of enzyme substrates and kits for the assessment of inhibition level as well as an apparatus designed for use in a process of the present invention.

  本发明提供了一种评估抑制剂对酶的可逆抑制水平的方法，特别是在评估医疗效果方面。在一个特别优选的实施方案中，公开了血管紧张素转换酶（ACE）抑制剂（ACEi）治疗的有效性。本发明还涉及酶底物的用途、评估抑制水平的试剂盒以及设计用于本发明过程的仪器。